Results from 317 newly diagnosed DMARD-naive patients with rheumatoid arthritis enrolled in the U-Act-Early trial show a clear reduction in the progression of bone erosions after 104 weeks of treatment with tocilizumab alone or in combination with methotrexate compared with treatment with methotrexate alone (P ≤ 0.023). The proportion of patients who showed no progression of erosions was also higher among those taking tocilizumab than methotrexate alone at weeks 52 and 104.
References
Teitsma, X. M. et al. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. Rheumatology (Oxford) http://dx.doi.org/10.1093/rheumatology/kex386 (2017)
Rights and permissions
About this article
Cite this article
Collison, J. Tocilizumab prevents progression of bone erosions. Nat Rev Rheumatol 14, 4 (2018). https://doi.org/10.1038/nrrheum.2017.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.196